# A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study

> **NCT05142254** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 64 (actual)

## Conditions studied

- Priapism Due to Sickle Cell Disease

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** Hydroxyurea
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05142254
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-01
- **Primary completion:** 2023-07-10
- **Final completion:** 2023-11-09
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142254, "A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05142254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*